Media Thread, page-12037

LC raced through her allotted 9 minutes. She avoided biotech jargon. She began by emphasising management’s fantastic experience in obtaining many FDA approvals in previous roles. IMU has about $130 m reserves. She said IMU’s SP has dropped from 60c to 12c ! However there are now 5 platforms that have produced at least one complete response. If these cases continue in remission, LC said, then it’s defined as a cancer cure! She emphasised allogeneic CAR T advantages over auto CAR T, and azer cel is producing impressive results. She talked about cf-33 and the bile duct CR. She glossed over onCARlytics - probably too hard to explain suffice to say it was a cf-33 variant.

This is how I remember the preso.